ACE inhibitor

Results: 229



#Item
171NDA[removed]S-021 Page 3 AVAPROâ (irbesartan) Tablets USE IN PREGNANCY

NDA[removed]S-021 Page 3 AVAPROâ (irbesartan) Tablets USE IN PREGNANCY

Add to Reading List

Source URL: www.fda.gov

Language: English - Date: 2006-03-14 13:56:22
172Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research  Memorandum

Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Memorandum

Add to Reading List

Source URL: www.fda.gov

Language: English - Date: 2006-03-14 13:56:21
173HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use COREG safely and effectively. See full prescribing information for COREG. •

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use COREG safely and effectively. See full prescribing information for COREG. •

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2011-01-31 14:17:54
174•	 History of serious hypersensitivity reaction (e.g., Stevens-Johnson syndrome, anaphylactic reaction, angioedema) to carvedilol or any of the components of COREG CR. (4) ----------------------- WARNINGS AND PRECAUTIO

• History of serious hypersensitivity reaction (e.g., Stevens-Johnson syndrome, anaphylactic reaction, angioedema) to carvedilol or any of the components of COREG CR. (4) ----------------------- WARNINGS AND PRECAUTIO

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2011-01-31 14:17:54
175• Renal failure: Monitor renal function after initiation and  HIGHLIGHTS OF PRESCRIBING INFORMATION periodically in patients with moderate to severe renal impairment (CrCL < 60 mL/min). If acute renal failure develops,

• Renal failure: Monitor renal function after initiation and HIGHLIGHTS OF PRESCRIBING INFORMATION periodically in patients with moderate to severe renal impairment (CrCL < 60 mL/min). If acute renal failure develops,

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2013-12-23 15:37:49
176•	  HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Valturna safely and effectively. See full prescribing information for Valturna.

• HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Valturna safely and effectively. See full prescribing information for Valturna.

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2011-05-05 14:18:21
177HIGHLIGHTS OF PRESCRIBING INFORMATION  • These highlights do not include all the information needed to use Valturna safely and effectively. See full prescribing information for

HIGHLIGHTS OF PRESCRIBING INFORMATION • These highlights do not include all the information needed to use Valturna safely and effectively. See full prescribing information for

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2011-02-11 15:07:03
178-----------------------CONTRAINDICATIONS------------------------  HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Diovan HCT safely and effectively. See full prescr

-----------------------CONTRAINDICATIONS------------------------ HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Diovan HCT safely and effectively. See full prescr

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2012-01-23 13:06:56
179HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TEKAMLO safely and effectively. See full prescribing information for TEKAMLO. Tekamlo (aliskiren and amlodipine) tab

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TEKAMLO safely and effectively. See full prescribing information for TEKAMLO. Tekamlo (aliskiren and amlodipine) tab

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2011-04-01 15:41:03
180-----------------WARNINGS AND PRECAUTIONS-----------------  HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Diovan HCT safely and effectively. See full prescribing

-----------------WARNINGS AND PRECAUTIONS----------------- HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Diovan HCT safely and effectively. See full prescribing

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2011-06-07 09:40:04